- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00296062
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
Dose-Dense and Dose-Intense Alternating Irinotecan/Capecitabine and Oxaliplatin/Capecitabine: Phase I in Solid Tumors and Phase II With Bevacizumab a First-Line Therapy of Advanced Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, irinotecan, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also block blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of capecitabine when given together with irinotecan and oxaliplatin with or without bevacizumab and to see how well they work in treating patients with metastatic or locally advanced colorectal cancer or other solid tumors that cannot be removed by surgery.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The study was originally intended to be Phase I/Phase II but it was terminated early because of toxicity of treatment and therefore never moved to the Phase II portion of the study.
OBJECTIVES:
- Determine the maximum tolerated dose (MTD) and dose-limiting toxicity of dose-dense and dose-intense capecitabine in combination with alternating full-dose irinotecan hydrochloride and oxaliplatin in patients with metastatic or locally advanced unresectable solid tumors. (phase I)
- Characterize the safety of the MTD in patients ≥ 65 years of age treated with this regimen. (phase I)
- Characterize the pharmacokinetics of this regimen in patients ≥ 65 years of age. (phase I)
- Characterize the functional status of patients ≥ 65 years of age at baseline and after study treatment, in terms of performance status, independence in activities, comorbidities, risk of malnutrition, and underlying depression. (phase I)
- Characterize the neurological status of all patients, in terms of muscle strength and sensation, at baseline and after study treatment. (phase I)
- Determine the clinical antitumor response in patients treated with this regimen. (phase I)
- Determine whether the addition of bevacizumab to dose-intense capecitabine in combination with alternating full-dose irinotecan hydrochloride and oxaliplatin as first-line treatment leads to an improved response rate in patients with metastatic colorectal cancer compared to that of published results of fluoropyrimidine/oxaliplatin, fluoropyrimidine/irinotecan/bevacizumab, and fluoropyrimidine/irinotecan regimens. (phase II)
- Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer. (phase II)
OUTLINE: This is a multicenter, phase I dose-escalation study of capecitabine followed by a phase II study.
- Phase I (all solid tumor patients): Patients receive oral capecitabine twice daily on days 1-7 and 15-21. Patients also receive irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses and oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients (with at least 1 patient < 65 years of age) experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
- Phase II (colorectal cancer patients): Patients receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses) and oxaliplatin (during even-numbered courses) as in phase I. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15 of each course.
After completion of study treatment, patients are followed periodically.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106-5065
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
DISEASE CHARACTERISTICS:
Phase I:
Histologically or cytologically confirmed solid tumor
- Metastatic OR locally advanced unresectable disease
- No curative therapy exists
Measurable or evaluable disease
- Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm with conventional techniques OR ≥ 10 mm with spiral CT scan
- No known brain metastases
Phase II:
Histologically or cytologically confirmed colorectal cancer
- Metastatic OR locally advanced unresectable disease
- Measurable disease (as defined in phase I)
- No tumor involving major blood vessels
- No evidence of CNS disease, including primary brain tumor or brain metastases
PATIENT CHARACTERISTICS:
- Karnofsky performance status 70-100%
- Life expectancy ≥ 12 weeks
Absolute neutrophil count (ANC) ≥ 1,500/mm^3
- ANC < 1,500/mm^3 allowed, if in the opinion of the investigator, this represents an ethnic or racial variation of normal
- Platelet count ≥ 100,000/mm^3
- Hemoglobin > 10.0 g/dL
- Bilirubin ≤ 1.5 mg/dL
- AST/ALT ≤ 2 times upper limit of normal (ULN)
- Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
- Urine protein:creatinine ratio < 1.0 OR protein < 1 g by 24-hour urine collection (phase II)
- PT/INR ≤ 1.5 unless on full-dose anticoagulants (phase II)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile female patients must use effective double-barrier contraception during and for 28 days (phase I) or 3 months (phase II) after completion of study treatment
- Fertile male patients must use effective contraception during and for 6 months after completion of study treatment
- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to capecitabine, irinotecan hydrochloride, oxaliplatin, or bevacizumab
No other uncontrolled illness including, but not limited to, any of the following:
- Ongoing or active infection
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Cardiac arrhythmia
- Psychiatric illness or social situation that would preclude study compliance
- No cardiac ischemia within the past 6 months (phase I)
- No New York Heart Association class II-IV congestive heart failure or symptomatic arrhythmia (phase II)
No arterial thrombotic events within the past 6 months including, but not limited to, any of the following (phase II):
- Transient ischemic attack
- Cerebrovascular accident
- Unstable angina or angina requiring surgical or medical intervention
- Myocardial infarction
- No clinically significant peripheral vascular disease (phase II)
- No history of hypertension unless well controlled (< 150/90 mm Hg) on an antihypertensive regimen (phase II)
- No evidence of bleeding diathesis or coagulopathy (phase II)
- No gastrointestinal (GI) perforation, abdominal fistula, or intra-abdominal abscess within the past 30 days (phase II)
No significant history of bleeding events (phase II)
- Patients with a history of significant bleeding episodes (e.g., hemoptysis or upper or lower GI bleeding) within the past 6 months are not eligible unless the source of bleeding has been resected
- No significant traumatic injury within the past 28 days (phase II)
- No serious or nonhealing wound, ulcer, or bone fracture (phase II)
- No peripheral neuropathy > grade 1
PRIOR CONCURRENT THERAPY:
- At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered (phase I)
- At least 2 weeks since prior immunotherapy or biologic therapy and recovered (phase I)
- No prior treatment for advanced or metastatic colorectal cancer (phase II)
- More than 12 months since prior adjuvant chemotherapy and/or biologic therapy (e.g., bevacizumab or cetuximab) and recovered (phase II)
- At least 4 weeks since prior radiotherapy and recovered
- No prior radiotherapy to the only site of measurable disease unless there is measurable disease progression within the radiation port after completion of radiotherapy
- No prior radiotherapy to ≥ 20% of the bone marrow
- More than 28 days since prior major surgical procedure* or open biopsy and recovered (phase II)
- More than 14 days since prior minor surgery* and recovered (phase II)
Concurrent full-dose anticoagulation (e.g., warfarin) allowed provided the following criteria are met (phase II):
- Patient has an in-range INR (between 2 and 3) and is on a stable dose of oral anticoagulants or a stable dose of low molecular weight heparin
- No active bleeding or pathological condition that carries a high risk of bleeding (e.g., known varices)
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent investigational agents
- No concurrent sargramostim (GM-CSF) NOTE: *Insertion of a vascular device is not considered major or minor surgery
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Phase II: Bevacizumab plus dose-intense capecitabine in combination with alternating full-dose irinotecan hydrochloride and oxaliplatin as first-line treatment leads to an improved response rate in patients with metastatic colorectal cancer
Lasso di tempo: Courses repeat every 28 days in the absence of unacceptable toxicity.
|
Courses repeat every 28 days in the absence of unacceptable toxicity.
|
Phase II: Determine the toxicity of bevacizumab in combination with this regimen in patients with metastatic colorectal cancer.
Lasso di tempo: at end of course 2 (each course is 28 days)
|
at end of course 2 (each course is 28 days)
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Phase I: Maximum tolerated dose in patients ≥ 65 years of age measured by CTC version 3.0 at end of Safety in the Elderly component of study
Lasso di tempo: Receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.
|
Receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Neoplasie
- Neoplasie per sede
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie gastrointestinali
- Malattie del colon
- Malattie intestinali
- Neoplasie intestinali
- Malattie del retto
- Neoplasie colorettali
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Inibitori enzimatici
- Antimetaboliti, Antineoplastici
- Antimetaboliti
- Agenti antineoplastici
- Inibitori della topoisomerasi
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Inibitori della topoisomerasi I
- Capecitabina
- Oxaliplatino
- Bevacizumab
- Irinotecano
Altri numeri di identificazione dello studio
- CASE1205 (Altro identificatore: Case Comprehensive Cancer Center)
- U01CA062502 (Sovvenzione/contratto NIH degli Stati Uniti)
- P30CA043703 (Sovvenzione/contratto NIH degli Stati Uniti)
- NCI-7325 (Altro identificatore: CTEP/NCI)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro colorettale
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteStadio III Adenocarcinoma della prostata AJCC v7 | Stadio II Adenocarcinoma prostatico AJCC v7 | Fase I Adenocarcinoma della prostata American Joint Committee on Cancer (AJCC) v7Stati Uniti
Prove cliniche su bevacizumab
-
National Cancer Institute (NCI)Attivo, non reclutanteCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Cistodenocarcinoma ovarico a cellule chiare | Adenocarcinoma endometrioide ovarico | Cistodenocarcinoma sieroso ovarico | Adenocarcinoma endometriale a cellule chiare | Adenocarcinoma... e altre condizioniStati Uniti
-
M.D. Anderson Cancer CenterReclutamentoCarcinoma epatocellulare in stadio IB AJCC v8 | Carcinoma epatocellulare in stadio II AJCC v8 | Carcinoma epatocellulare resecabile | Carcinoma epatocellulare stadio I AJCC v8 | Stadio IA Carcinoma epatocellulare AJCC v8Stati Uniti
-
National Cancer Institute (NCI)CompletatoAdenocarcinoma cervicale | Carcinoma adenosquamoso cervicale | Carcinoma a cellule squamose della cervice, non altrimenti specificato | Stadio IVA Cancro cervicale AJCC v6 e v7 | Carcinoma cervicale ricorrente | Cancro cervicale in stadio IV AJCC v6 e v7 | Stadio IVB Cancro cervicale AJCC v6 e v7Stati Uniti
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)ReclutamentoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Adenocarcinoma endometrioide ovarico | Adenocarcinoma ovarico a cellule chiare | Adenocarcinoma della tuba di Falloppio | Adenocarcinoma sieroso delle tube di Falloppio | Adenocarcinoma... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteMelanoma cutaneo di stadio IV AJCC v6 e v7 | Melanoma cutaneo in stadio IIIC AJCC v7 | Melanoma non resecabileStati Uniti
-
National Cancer Institute (NCI)NRG OncologyCompletatoGlioblastoma | Gliosarcoma | Glioblastoma ricorrente | Oligodendrogliomi | Glioblastoma a cellule giganti | Neoplasia cerebrale ricorrenteStati Uniti, Canada
-
National Cancer Institute (NCI)ReclutamentoSarcoma metastatico della parte molle alveolare | Sarcoma della parte molle alveolare non resecabileStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteAdenocarcinoma endometrioide ovarico | Adenocarcinoma sieroso peritoneale primario di alto grado | Adenocarcinoma endometrioide delle tube di Falloppio | Carcinoma delle tube di Falloppio resistente al platino | Carcinoma peritoneale primario resistente al platino | Adenocarcinoma sieroso ovarico... e altre condizioniStati Uniti, Canada
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletatoCarcinoma ricorrente delle tube di Falloppio | Carcinoma ovarico ricorrente | Carcinoma peritoneale primitivo ricorrente | Carcinoma delle tube di Falloppio resistente al platino | Carcinoma peritoneale primario resistente al platino | Carcinoma ovarico resistente al platino | Carcinoma ovarico... e altre condizioniStati Uniti
-
National Cancer Institute (NCI)Attivo, non reclutanteGlioblastoma ricorrenteStati Uniti